Fred Saad, MD, University of Montreal Hospital Center, highlights, "Results from ACIS, a Randomized, Placebo Controlled Double-Blind Phase 3 Study of Apalutamide and Abiraterone Acetate Plus Prednisone Versus Abiraterone in Patients with Chemo-Naive Castration-Resistant Prostate Cancer."
